Skip to main content

Helixgate

Skip to main content

Helixgate

BioPharma Dive – AI / Data

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

Published

on

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as a “steal” — may leave room for a competing bid.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma Dive – AI / Data

Helixgate AI & Biotech Collaboration Series + Helixgate Industry Nights

Published

on

By

Helixgate AI & Biotech Collaboration Series + Helixgate Industry Nights brings together leaders and professionals from biotechnology, pharma, artificial intelligence, science, technology, medicine and healthcare for an evening of industry insights, networking and collaboration.

Date: October 22, 2026
Location: Del Mar Social, San Diego, California

Reserve your spot and purchase tickets on Eventbrite:
https://www.eventbrite.com/e/helixgate-ai-biotech-collaboration-series-helixgate-industry-nights-tickets-1998469781915?aff=oddtdtcreator

Continue Reading

BioPharma Dive – AI / Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

Published

on

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. 

Continue Reading

BioPharma Dive – AI / Data

Novartis targets Xolair successor in buyout of startup Excellergy

Published

on

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine. 

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read